Sino Biological/IFN-beta Protein, Human, Recombinant/1/10704-HNAS
商品编号：
10704-HNAS
品牌：
sinobiological
市场价：
¥0.00
美元价：
0.00
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
IFN-beta Protein, Human, Recombinant: Product Information
Purity
> 95 % as determined by SDS-PAGE
Endotoxin
< 1.0="" eu="" per="" μg="" of="" the="" protein="" as="" determined="" by="" the="" lal="">
Activity
Measured in antiviral assays using WISH cells infected with vesicular stomatitis virus. The ED50 for this effect is typically 2-20 pg/mL.
Protein Construction
A DNA sequence encoding the human IFNβ (P01574) (Met1-Asn187) was expressed.
Accession#
P01574
Expressed Host
CHO Stable Cells
Species
Human
Predicted N Terminal
Met 22
Molecule Mass
The recombinant human IFNβ consists of 166 amino acids and predicts a molecular mass of 20 KDa. It migrates as an approximately 20-23 KDa band in SDS-PAGE under reducing conditions.
Formulation
Lyophilized from sterile 10mM NaAC, 40mM Arg, 0.12mg/ml Met, 146mg/ml Sucrose, 0.1% PF-68, pH 4.5Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
IFN-beta Protein, Human, Recombinant: Images
Measured in antiviral assays using WISH cells infected with vesicular stomatitis virus. The ED50 for this effect is typically 2-20 pg/mL.
IFN-beta Protein, Human, Recombinant: Synonyms
IFB Protein, Human; IFF Protein, Human; IFN-beta Protein, Human; IFNB Protein, Human; Interferon beta Protein, Human
IFN-beta Background Information
Interferons (IFNs) are natural glycoproteins belonging to the cytokine superfamily and are produced by the cells of the immune system of most vertebrates in response to challenges by foreign agents such as viruses, parasites, and tumor cells. Interferon-beta (IFN beta) is an extracellular protein mediator of host defense and homeostasis. IFN beta has well-established direct antiviral, antiproliferative, and immunomodulatory properties. Recombinant IFN beta is approved for the treatment of relapsing-remitting multiple sclerosis. The recombinant IFN beta protein has the theoretical potential to either treat or causes autoimmune neuromuscular disorders by altering the complicated and delicate balances within the immune system networks. It is the most widely prescribed disease-modifying therapy for multiple sclerosis (MS). Large-scale clinical trials have established the clinical efficacy of IFN beta in reducing relapses and slowing disease progression in relapsing-remitting MS. IFN beta therapy was shown to be comparably beneficial for opticospinal MS (OSMS) and conventional MS in Japanese. IFN beta is effective in reducing relapses in secondary progressive MS and may have a modest effect in slowing disability progression. In addition to the common antiviral activity, IFN beta also induces increased production of the p53 gene product which promotes apoptosis and thus has a therapeutic effect against certain cancers. The role of IFN-beta in bone metabolism could warrant its systematic evaluation as a potential adjunct to therapeutic regimens of osteolytic diseases. Furthermore, IFN beta might play a beneficial role in the development of chronic progressive CNS inflammation.
- Cancer Immunotherapy
- Immune Checkpoint
- Immunotherapy
- Targeted Therapy
Full Name
interferon, beta 1, fibroblast
References
- Kohriyama T, et al. (2008) Interferon-beta treatment for multiple sclerosis and predictors of response. Nippon Rinsho. 66(6): 1119-26.
- Stbgen JP. (2009) Recombinant interferon-beta therapy and neuromuscular disorders. J Neuroimmunol. 212(1-2): 132-41.
- Abraham AK, et al. (2009) Mechanisms of interferon-beta effects on bone homeostasis. Biochem Pharmacol. 77(12): 1757-62.
Human IFN-beta Proteins
- IFN-beta Protein, Human, Recombinant (hFc Tag)10704-H02H
Mouse IFN-beta Proteins
- IFN-beta Protein, Mouse, Recombinant (hFc Tag)50708-M02H
- IFN-beta Protein, Mouse, Recombinant50708-MCCH
Rhesus IFN-beta Proteins
- IFN-beta Protein, Rhesus, Recombinant (mFc Tag)90104-C05H
- A potent in vivo anti-tumor efficacy of novel recombinant type I interferonAuthorZhang, K;Yin, XF;Yang, YQ;Li, HL;Xu, YN;Chen, LY;Liu, XJ;Yuan, SJ;Fang, XL;Xiao, J;Wu, S;Xu, H;Chu, L;Katlinski, KV;Katlinskaya, YV;Guo, RB;Wei, GW;Wang, DC;Liu, X;Fuchs, SY;Year2016JournalClin. Cancer Res.ApplicationbindingFoldedExpand
- A potent in vivo anti-tumor efficacy of novel recombinant type I interferonAuthorZhang, K;Yin, XF;Yang, YQ;Li, HL;Xu, YN;Chen, LY;Liu, XJ;Yuan, SJ;Fang, XL;Xiao, J;Wu, S;Xu, H;Chu, L;Katlinski, KV;Katlinskaya, YV;Guo, RB;Wei, GW;Wang, DC;Liu, X;Fuchs, SY;Year2016JournalClin. Cancer Res.ApplicationbindingFoldedExpand
- Human Virus-Derived Small RNAs Can Confer Antiviral Immunity in MammalsAuthorQiu, Y;Xu, Y;Zhang, Y;Zhou, H;Deng, YQ;Li, XF;Miao, M;Zhang, Q;Zhong, B;Hu, Y;Zhang, FC;Wu, L;Qin, CF;Zhou, X;Year2017JournalImmunityApplicationcell-basedPubMed ID: 28636969FoldedExpand
- Influenza Virus NS1 Protein RNA-Interactome Reveals Intron TargetingAuthorZhang, L;Wang, J;Muñoz-Moreno, R;Kim, M;Sakthivel, R;Mo, W;Shao, D;Anantharaman, A;García-Sastre, A;Conrad, NK;Fontoura, BMA;Year2018JournalJ. Virol.Applicationcell-basedPubMed ID: 30258002FoldedExpand
- FAF1 Regulates Antiviral Immunity by Inhibiting MAVS but Is Antagonized by Phosphorylation upon Viral InfectionAuthorDai, T;Wu, L;Wang, S;Wang, J;Xie, F;Zhang, Z;Fang, X;Li, J;Fang, P;Li, F;Jin, K;Dai, J;Yang, B;Zhou, F;van Dam, H;Cai, D;Huang, H;Zhang, L;Year2018JournalCell Host MicrobeApplicationcell-basedPubMed ID: 30472208FoldedExpand
If you couldn"t find the specific citation, you can:
- Find All Citations
- Submit a CitationGet a Publication Reward
- Leave Us a Message
E.coli protein expression service
Mammalian transient protein expression service
Baculovirus-insect expression service
Stable cell line development service (CHO / HEK293)
品牌介绍
北京义翘神州科技股份有限公司（Sino Biological Inc.）是一家从事生物试剂研发、生产、销售并提供技术服务的生物科技公司，主要业务包括重组蛋白、抗体、基因和培养基等产品，以及重组蛋白、抗体的开发和生物分析检测等服务。义翘神州为全球的药品研发企业和生命科学研究机构提供高质量的生物试剂产品和高水平的技术服务。公司目前生产和销售的现货产品种类超过 4.6 万种，其中重组蛋白约 6,000 种，包括超过 3,800 种人源细胞表达重组蛋白产品，能够全面满足客户对于最接近人体天然蛋白结构和性质的重组蛋白需求；公司还能提供约 12,000 种抗体，其中单克隆抗体数量约 4,600 种，能够覆盖生命科学研究的多个领域，为分子生物学、细胞生物学、免疫学、发育生物学、干细胞研究等基础科研方向和创新药物研发提供「一站式」生物试剂产品和技术服务。义翘神州的客户涵盖大学、科研院所、医药研发企业等国内外各类生物研发单位。目前公司已经在美国、欧洲建立了子公司，已成为生物试剂行业国内领先的科技公司之一。
联络我们
